Transcript
((Rami Komrokji, MD))
Recently, the landscape of acute myeloid leukemia treatment has been changing.
More institutions are moving to an outpatient treatment approach and, in my experience, a part of this consideration is due to volume in hospitals and patient preference.
Treatment in the inpatient/outpatient setting, also known as an IPOP treatment plan, enables appropriate patients to receive induction in an outpatient setting, with a planned inpatient admission for continued monitoring and subsequent management of complications that may arise.
Furthermore, the use of oral prophylactic antimicrobial agents has increased over the last several years, and outpatient transfusion support has become standard.
Due to these advancements, some patients with AML may now be supported in an IPOP setting.
The potential benefit of an IPOP plan is that patients can be hospitalized for less time during treatment.
INDICATION
VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t‑AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
IMPORTANT SAFETY INFORMATION